company background image
000627 logo

Hubei Biocause Pharmaceutical SZSE:000627 Stock Report

Last Price

CN¥4.01

Market Cap

CN¥19.8b

7D

2.3%

1Y

28.9%

Updated

23 Nov, 2024

Data

Company Financials

Hubei Biocause Pharmaceutical Co., Ltd.

SZSE:000627 Stock Report

Market Cap: CN¥19.8b

000627 Stock Overview

Primarily provides life and motor insurance products in China. More details

000627 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Hubei Biocause Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hubei Biocause Pharmaceutical
Historical stock prices
Current Share PriceCN¥4.01
52 Week HighCN¥4.95
52 Week LowCN¥1.61
Beta0.72
11 Month Change6.37%
3 Month Change133.14%
1 Year Change28.94%
33 Year Change26.90%
5 Year Change-40.15%
Change since IPO708.87%

Recent News & Updates

Hubei Biocause Pharmaceutical Co., Ltd.'s (SZSE:000627) Shares Leap 43% Yet They're Still Not Telling The Full Story

Oct 23
Hubei Biocause Pharmaceutical Co., Ltd.'s (SZSE:000627) Shares Leap 43% Yet They're Still Not Telling The Full Story

Further Upside For Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Could Introduce Price Risks After 32% Bounce

Sep 05
Further Upside For Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Could Introduce Price Risks After 32% Bounce

Recent updates

Hubei Biocause Pharmaceutical Co., Ltd.'s (SZSE:000627) Shares Leap 43% Yet They're Still Not Telling The Full Story

Oct 23
Hubei Biocause Pharmaceutical Co., Ltd.'s (SZSE:000627) Shares Leap 43% Yet They're Still Not Telling The Full Story

Further Upside For Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Could Introduce Price Risks After 32% Bounce

Sep 05
Further Upside For Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Could Introduce Price Risks After 32% Bounce

Improved Revenues Required Before Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Find Their Feet

Jun 10
Improved Revenues Required Before Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Find Their Feet

Fewer Investors Than Expected Jumping On Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627)

Mar 05
Fewer Investors Than Expected Jumping On Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627)

Shareholder Returns

000627CN InsuranceCN Market
7D2.3%-2.1%-2.1%
1Y28.9%24.2%2.8%

Return vs Industry: 000627 exceeded the CN Insurance industry which returned 24.2% over the past year.

Return vs Market: 000627 exceeded the CN Market which returned 2.8% over the past year.

Price Volatility

Is 000627's price volatile compared to industry and market?
000627 volatility
000627 Average Weekly Movement15.5%
Insurance Industry Average Movement4.6%
Market Average Movement8.4%
10% most volatile stocks in CN Market12.7%
10% least volatile stocks in CN Market5.7%

Stable Share Price: 000627's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 000627's weekly volatility has increased from 9% to 15% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a1,765Wenxia Zhouwww.biocause.com

Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride.

Hubei Biocause Pharmaceutical Co., Ltd. Fundamentals Summary

How do Hubei Biocause Pharmaceutical's earnings and revenue compare to its market cap?
000627 fundamental statistics
Market capCN¥19.81b
Earnings (TTM)-CN¥771.87m
Revenue (TTM)CN¥40.70b

0.5x

P/S Ratio

-25.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
000627 income statement (TTM)
RevenueCN¥40.70b
Cost of RevenueCN¥39.02b
Gross ProfitCN¥1.68b
Other ExpensesCN¥2.45b
Earnings-CN¥771.87m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.16
Gross Margin4.12%
Net Profit Margin-1.90%
Debt/Equity Ratio48.6%

How did 000627 perform over the long term?

See historical performance and comparison